Adenoviridae Infections clinical trials
The registry lists 136 studies for Adenoviridae Infections across more than 10 countries. 34 are recruiting or about to start. 57 of them are mainly about Adenoviridae Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Get an email when these change. Save the Adenoviridae Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (10) · Baylor College of Medicine (7) · AlloVir (6) · Chimerix (6) · Assistance Publique - Hôpitaux de Paris (4) · ReiThera Srl (4) · McMaster University (3) · Children's Hospital Medical Center, Cincinnati (2)
What is being tested here
Drugs under test in Adenoviridae Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 10, phase 3 first
- Jun 2027Adaptive RCT of Corticosteroids for Severe Adenovirus Pneumonia in Adults · Phase 3 · Qingyuan Zhan
- Nov 2026Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma · Huashan Hospital
- Dec 2026A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System® · University Hospital, Basel, Switzerland
- Dec 2026A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors · EpicentRx, Inc.
- Dec 2026Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection · New York Medical College
- Jan 2027Donor-Derived Viral Specific T-cells (VSTs) · Children's Hospital Medical Center, Cincinnati
- Mar 2027Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. · TILT Biotherapeutics Ltd.
- Mar 2027Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT · Sumithira Vasu
- May 2027TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT. · Baylor College of Medicine
- Jul 2027Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. · Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Who these studies take
Of the 25 Adenoviridae Infections studies recruiting now, 9 (36%) set no upper age limit and 12 (48%) stop at 75 or younger. 17 (68%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (16%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 16 (64%) | 16 (64%) |
| 18 | 23 (92%) | 23 (92%) |
| 30 | 21 (84%) | 21 (84%) |
| 40 | 20 (80%) | 20 (80%) |
| 50 | 20 (80%) | 20 (80%) |
| 65 | 19 (76%) | 19 (76%) |
| 75 | 15 (60%) | 15 (60%) |
| 85 | 12 (48%) | 12 (48%) |
Across all 136 studies, recruiting or not: 43% stop at 75 or younger and 33% at 65; 46% take children; 2% are for women only and 5% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Adenoviridae Infections studies take
Of 23 phase 1 interventional studies under Adenoviridae Infections, half reached primary completion within 48 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 48 mo42–101 · 23 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
Studies
Recruiting first, then most recently updated. Showing 50 of 136. Browse all 136 → or search them.
- The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known ImmunocompromiseRecruitingNCT010117121 country
- TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.RecruitingNCT04013802Phase 11 country
- Viral Infections in Healthy and Immunocompromised HostsRecruitingNCT013060841 country
- Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus InfectionRecruitingNCT03266627Phase 21 country
- 25BT056: Basket Study of Viral Cytotoxic T LymphocytesNot yet recruitingNCT07873970Early Phase 1
- A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCTRecruitingNCT07387367Phase 313 countries
- A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal CancersRecruitingNCT07544589Phase 11 country
- Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCTRecruitingNCT03665675Early Phase 11 country
- TETRAVI Expanded Access ProgramAvailableNCT07104591
- Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC AloneRecruitingNCT07225972Phase 31 country
- ELderly REspiratory VIral CohortNot yet recruitingNCT07813481
- Donor-Derived Viral Specific T-cells (VSTs)RecruitingNCT02048332Phase 1/21 country
- Third Party Viral Specific T-cells (VSTs)RecruitingNCT02532452Phase 21 country
- YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)RecruitingNCT07793500Early Phase 11 country
- R-MVST Cells for Treatment of Viral Infections in Children and Young AdultsRecruitingNCT06926894Phase 11 country
- YH02 Injection for Intra-tumor Injection Therapy in Advanced Solid Tumors With Unresponsive or Failure-Treated CasesRecruitingNCT07697937Phase 21 country
- Anti-viral T-cell Therapy by Gamma CaptureEnrolling by invitationNCT06027879Phase 1/21 country
- R-MVST Cells for Treatment of Viral InfectionsRecruitingNCT05183490Phase 11 country
- Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy VolunteersRecruitingNCT03878121Phase 11 country
- Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent GlioblastomaRecruitingNCT07538128Early Phase 11 country
- Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.Enrolling by invitationNCT06763965Phase 1/21 country
- Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell TransplantationRecruitingNCT05664126Phase 21 country
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT073589101 country
- Adaptive RCT of Corticosteroids for Severe Adenovirus Pneumonia in AdultsNot yet recruitingNCT07152600Phase 3
- A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid TumorsEnrolling by invitationNCT06215846Phase 11 country
- Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised ImmunityRecruitingNCT06909110Phase 1/21 country
- Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV InfectionsRecruitingNCT04832607Phase 36 countries
- Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus InfectionsRecruitingNCT04722029Phase 1/21 country
- A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®RecruitingNCT02007356Phase 21 country
- Study of Viral Respiratory InfectionsNot yet recruitingNCT067643811 country
- Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant GliomaRecruitingNCT06585527Phase 11 country
- Effectiveness of a Single Dose of Betamethasone in Children With Symptomatic Adenovirus InfectionRecruitingNCT06299813Phase 31 country
- Adoptive T-cell Therapy for Resistant Viral Infections After Allogeneic HSCTNot yet recruitingNCT05075837Phase 1
- Virus and Bronchial Epithelium in Children and the ElderlyRecruitingNCT06224062Not applicable1 country
- Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic InfectionsTerminatedNCT03159364Phase 1/21 country
- Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral InfectionTerminatedNCT06999603Phase 22 countries
- A Phase 2a Study of IV BCV in Subjects With Adenovirus InfectionCompletedNCT04706923Phase 21 country
- Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer PatientsTerminatedNCT05101213Phase 11 country
- A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid TumorsActive, not recruitingNCT04673942Phase 21 country
- Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBVTerminatedNCT04364178Phase 1/21 country
- Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.Active, not recruitingNCT05271318Phase 1/22 countries
- Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory VirusesActive, not recruitingNCT05864118Not applicable1 country
- Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder CancerWithdrawnNCT02143804Phase 21 country
- TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 MonotherapyCompletedNCT04695327Phase 11 country
- LOAd703 Oncolytic Virus Therapy for Pancreatic CancerCompletedNCT02705196Phase 1/21 country
- Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirusCompletedNCT01325636Phase 1/21 country
- Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by AerosolCompletedNCT05094609Phase 11 country
- Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)CompletedNCT01945814Phase 11 country
- Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell TransplantationActive, not recruitingNCT03475212Phase 1/21 country
- Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck CancerCompletedNCT03754933Phase 1/21 country